Best Tech Companies To Buy Right Now

In this video, Austin Smith describes Apple's big opportunity: its iPhone. An unsubsidized iPhone costs about $650, but most people pay around $200 for an iPhone, and if a carrier doesn't subsidize the smartphone, customers will go to someone who will. This results in a profit margin 10 times greater than the margin for PCs. The smartphone market continues growing, and although Apple might lose market share, Austin says, its popularity and carrier subsidies allow Apple to gain great profit margins. Consequently, Apple enjoys a great cash balance to work with for future projects and innovations.

See the video for more details.

There's no doubt that Apple is at the center of technology's largest revolution ever and that longtime shareholders have been handsomely rewarded, with more than 1,000% gains. However, there is a debate raging as to whether Apple remains a buy. The Motley Fool's senior technology analyst and managing bureau chief, Eric Bleeker, is prepared to fill you in on reasons to buy and reasons to sell Apple and what opportunities are left for the company (and your portfolio) going forward. To get instant access to his latest thinking on Apple, simply click here now.

Best Tech Companies To Buy Right Now: Zix Corporation(ZIXI)

Zix Corporation provides Internet-based applications in software as a service model that enables the use of secure email for sensitive information exchange primarily in the healthcare, financial services, insurance, and government sectors in the United States. It offers email encryption service, a secure messaging service, which allows an enterprise to use policy-driven rules to determine which emails should be sent securely to comply with regulations or policies. The company also provides a solution that analyzes and encrypts email communications. Its services offer users the ability to deliver encrypted email to any email user at any email address by using the ZixCorp Best Method of Delivery protocol that automatically determines the direct and appropriate means of delivery, based on the sender?s and recipient?s communications environment and preferences. Zix Corporation sells its services through a direct sales force, and a network of resellers and other distribution partners. The company was formerly known as ZixIt Corporation and changed its name to Zix Corporation in 2002. Zix Corporation was founded in 1983 and is headquartered in Dallas, Texas.

Advisors' Opinion:

• [By Monica Gerson]

  Zix (NASDAQ: ZIXI) shares reached a new 52-week high of $4.82. ZixCorp's trailing-twelve-month profit margin is 18.08%.

  Official Payments Holdings (NASDAQ: OPAY) shares surged 0.23% to touch a new 52-week high of $8.65. Official Payments shares have jumped 87.61% over the past 52 weeks, while the S&P 500 index has gained 16.68% in the same period.

Best Tech Companies To Buy Right Now: Jds Uniphase Canad Exchangeable(JDU.TO)

JDS Uniphase Corporation provides communications test and measurement solutions, and optical products for telecommunications service providers, wireless operators, cable operators, network-equipment manufacturers, and enterprises worldwide. The company?s Communications Test and Measurement segment supplies instruments, software, and services to enable the design, deployment, and maintenance of communication equipment and networks. Its product portfolio consists of test tools, platforms, software, and services for wireless and fixed networks. The company?s Communications and Commercial Optical Products segment offers components, modules, subsystems, and solutions that are used by communications equipment providers for telecommunications and enterprise data communications. This segment?s products comprise transmitters, receivers, amplifiers, ROADMs, optical transceivers, multiplexers and demultiplexers, switches, optical-performance monitors and couplers, splitters, and c irculators, which enable the transmission of video, audio, and text data through fiber-optic cables. It also provides various laser products, including diode, direct-diode, diode-pumped solid-state, fiber, and gas lasers for micromachining, materials processing, bioinstrumentation, consumer electronics, graphics, medical/dental, and optical pumping; and photovoltaic products, such as concentrated photovoltaic cells and receivers for generating energy from sunlight, as well as fiber optic-based systems for delivering and measuring electrical power. The company?s Advanced Optical Technologies segment offers optical solutions for security and brand-differentiation applications; and thin film coatings for a range of public and private-sector markets. This segment also provides multilayer product-security solutions that deliver overt, covert, forensic, and digital product and document verification. JDS Uniphase Corporation was founded in 1979 and is headquartered in Milpitas, Ca lifornia.

Best Dividend Companies To Watch In Right Now: Virtusa Corporation(VRTU)

Virtusa Corporation provides information technology (IT) consulting, technology implementation, and application outsourcing services in North America, Europe, the Middle East, India, and Sri Lanka. The company?s IT consulting services include application inventory and portfolio assessment, business/technology alignment analysis, IT strategic planning, and quality assurance process consulting; enterprise architecture analysis, technology roadmaps, product evaluation and selection, and business process analysis and design services; and program governance and change management, program management planning, and IT process consulting. Its technology implementation services include application development, package implementation and integration, software product engineering, business process management implementation, and enterprise content management; systems consolidation and rationalization, technology migration and porting, and Web-enablement of legacy applications; data ma nagement and transformation, and business intelligence, reporting and decision support services; and testing frameworks, automation of test data and cases, and test cycle execution. The company?s application outsourcing services include production support, maintenance and enhancement of custom-built and package-based applications, and ongoing software engineering services; systems and database administration, and monitoring; and outsourcing of quality assurance planning, and preparation and execution of test cases, scripts, and data. The company primarily serves communications and technology, banking, financial services, insurance, media, and information industries. The company was formerly known as eRunway, Inc. and changed its name to Virtusa Corporation in April 2002. Virtusa Corporation was incorporated in 1996 and is headquartered in Westborough, Massachusetts.

Best Tech Companies To Buy Right Now: Mitek Systems Inc (MITK.PH)

Mitek Systems, Inc. (Mitek), incorporated in 1986, is engaged in the development, sale and service of software solutions related to mobile imaging applications and intelligent recognition software. Mitek is applying its technology and in image correction, optical character recognition and intelligent data extraction to mobile devices. Using Mitek Mobile Apps, camera-equipped smartphone users can deposit checks, pay bills, save receipts and fax documents. Users simply take a picture of the document and its products corrects image distortion, extracting relevant data, routing images to their desired location, and processing transactions through users��financial institutions. It has developed and deployed Mobile Deposit, a software application that allows users to deposit a check using their smartphone camera. It has developed and deployed Mobile Receipt, a receipt archival and expense report application, and Mobile Phax, a mobile document faxing application. Its Mobile Photo Bill Pay, a mobile bill paying application that allows users to pay their bills using their smartphone camera. During fiscal year ended September 30, 2010 (fiscal 2010), it had one operating segment based on its product and service offerings.

IMagePROVE Technology Products

Using IMagePROVE, the Company has a suite of business productivity applications for camera-equipped smartphones, including the iPhone and selected BlackBerry, Android and Windows Mobile handsets. It has four products that use its IMagePROVE technology Mobile Deposit, Mobile Receipt, Mobile Phax and Mobile Photo Bill Pay. Its products are used in the financial services industry. It has secured sales partnerships with system integrators for the financial services industry, including Fiserv, FIS, NCR, Jack Henry, Wausau, BankServ, RDM, J&B Software and Bluepoint Solutions.

The Company�� Mobile Deposit is the smartphone application allows banks to accept check dep osits through photos of checks taken with camera-equipped s! m! artphones. Mobile Deposit allows users to make deposits by photographing the front and back of a check and submitting the item electronically to their bank from their smartphone. Its Mobile Receipt is designed to convert the photo of a receipt taken with a smartphone into an image and with a single touch, converts the data into a professional looking expense report. Mobile Phax allows user to take a photo of any letter sized document or page and send it as a portable document format (PDF) file to any e-mail address or fax machine.

The Company�� Mobile Photo Bill Pay allows users to take pictures of their bills with their smartphone cameras and its Mobile Photo Bill Pay product correct image distortion, reading relevant data and processing the transactions through the users��banks. The payment is made electronically by debiting the users checking account and using existing online bill pay systems. With Mobile Photo Bill Pay, users can submit electronic paymen ts from their smartphones without having to write checks, lick stamps, visit a payment location or even use their personal computers.

ImageNet Intelligent Character Recognition Toolkits

The Company�� ImageNet products are designed to provide remittance processing, proof of deposit and lock box processing applications. Its products are used to reduce manual labor by automatically extracting amounts and routing information from checks and distinguishing between common document types, such as personal and business checks, substitute checks, pre-authorized drafts and other document types specified by customers. It sells ImageNet suite of products to its channel partners, who resell them as integrated components of their solutions and services. Its ImageNet suite of products includes ImageNet Prep & ID, ImageNet Payments, ImageNet Data Capture and ImageNet Signatures.

ImageNet Prep & ID is a software toolkit that is designed to provide aut omatic form information document (ID), form registratio! n and! fo! rm/tem! plate removal. Image Net Prep & ID reduces the image size by removing information, such as pre-printed text, lines, and boxes; leaving only the filled-in data. ImageNet Payments allows for the automatic reading of machine and hand print information found on scanned documents and forms from any structured form, as well as bank documents, such as checks, deposit slips, and remittance coupons. ImageNet Payments integrates technology components from the CheckReader product that it licenses from a vendor that is designed to read rates of the currency and legal amounts of checks drawn on the United States and Canadian financial institutions.

ImageNet Data Capture is a software toolkit that captures data from types of unstructured business documents. ImageNet Data Capture is used in data capture applications where data must be found and extracted from documents that have no pre-determined format or layout, but share common data elements. ImageNet Data Capture is design ed to locate this data on documents using contextual, positional, format and keyword specific information. It has supplied ImageNet Data Capture as a stand alone application programming interface (API) to several original equipment manufacturers (OEMs) in the document processing field. ImageNet Signatures is a software toolkit that locates, extracts and verifies signatures in any document. It encodes each signature and compares it with encoded reference examples rather than comparing actual images. Its image analytics encode 60 characteristics of each signature, which allows for accurate signature fraud detection.

FraudProtect Systems

The Company�� FraudProtect System is an automated software application designed to allow banks to detect check fraud from forged signatures and counterfeit checks, as well as the detection of pre-authorized drafts and payee name alterations. Its FraudProtect suite of products includes FraudProtect SDK, PADsafe and Pa yeeFind. Its FraudProtect SDK is a toolkit designe! d to dete! c! t check f! raud and forgery using image analytics to uncover inconsistencies and alterations in checks as they are processed by banks. These products are sold to OEMs and system integrators and can detect forged or illegally modified checks. Its PADsafe product detects fraudulent preauthorized drafts (PADs). PADsafe automatically identifies PADs from checks, and then notifies the user of fraudulent transactions, reducing and preventing the unauthorized withdrawal of funds. Its PayeeFind product is designed to prevent payee-altered checks from clearing.

ImageScore

ImageScore is the Company�� Check 21 readiness solution for any financial institution that truncates or uses check images in an accounts receivables conversion environment. Integrated solution providers for financial institutions can also buy ImageScore to enhance their products. ImageScore is designed to analyze check images to provide the usability and information needed to help financial institut ions act in accordance with regulatory and industry mandates.

Best Tech Companies To Buy Right Now: Morningstar Inc.(MORN)

Morningstar, Inc., together with its subsidiaries, provides independent investment research to investors worldwide. The company operates in two segments, Investment Information and Investment Management. The Investment Information segment offers data, software, and research products and services for individual investors, financial advisors, and institutional clients. It provides Licensed Data, a set of investment data spanning various investment databases, including real-time pricing data available through electronic data feeds; Morningstar Advisor Workstation, a Web-based investment planning system; Morningstar.com, a membership service and Internet advertising space; Morningstar Direct, a Web-based institutional research platform; integrated Web tools to build customized Websites or enhance existing sites; Morningstar Principia, a CD-ROM-based investment research and planning software; Morningstar commodity data that provides data and analytics for the energy, financial, and agriculture sectors; equity and corporate credit research; and Morningstar structured credit ratings and research services. This segment also offers various financial communications materials, real-time data and desktop software, investment software, and investment indexes, as well as various print and online publications. The Investment Management segment offers various products and services, such as Investment Consulting that focuses on investment monitoring and asset allocation for funds of funds, including mutual funds and variable annuities; Retirement Solutions comprising the Morningstar Retirement Manager and Advice by Ibbotson platforms; and Morningstar Managed Portfolios, a asset management service includes series of mutual fund, exchange-traded fund, and stock portfolios. This segment serves banks, brokerage firms, insurance companies, mutual fund companies, and retirement plan sponsors and providers. Morningstar, Inc. was founded in 1984 and is headquartered in Chicago, Illinois.

Advisors' Opinion:

• [By Reuters]

  Simon Dawson/Bloomberg via Getty Images TORONTO -- BlackBerry reported a quarterly loss of nearly $1 billion Friday, in line with last week's warning, days after accepting its largest shareholder's tentative $4.7 billion bid to take it out of the public eye. BlackBerry (BBRY), which had warned of poor results on Sept. 20, said its net loss for the second quarter ended on Aug. 31 was $965 million, or $1.84 a share. Revenue fell 45 percent to $1.6 billion from a year earlier. The loss included a writedown of about $934 million for unsold Z10 phones, a touchscreen model that the company had hoped would reverse its fading fortunes. The phone has sold badly with business and consumer customers alike. "This write-off is very real," said Morningstar (MORN) analyst Brian Colello. "They bought a lot of inventory hoping to sell it. The auditors were not convinced that BlackBerry can sell it or sell it at prices that the company was hoping for. We see no reason to be more optimistic than them." Excluding the Z10 writedown and restructuring costs, BlackBerry reported a loss of $248 million, or 47 cents a share. The company plans to shed 4,500 jobs, or more than one-third of its workforce, as it shrinks to focus on corporate and government customers. It will not host the typical post-results call for investors after signing a tentative $9-a-share agreement to be acquired by a consortium led by Fairfax Financial, its largest shareholder, Monday. The Waterloo, Ontario-based company's steep revenue decline and mounting losses have revived fears that BlackBerry, a pioneer in the smartphone sector, faces an ignominious death. "We are very disappointed with our operational and financial results this quarter and have announced a series of major changes to address the competitive hardware environment and our cost structure," Chief Executive Officer Thorsten Heins said in the earnings statement. BlackBerry said Heins wasn't available for an interview. The company said it

• [By Reuters]

  Mark Lennihan/APAbercrombie & Fitch CEO Michael Jeffries An Abercrombie & Fitch shareholder urged the teen apparel retailer to replace Chief Executive Officer Mike Jeffries after his contract expires in February, failing which the company should look to sell itself. Engaged Capital, which owns less than 1 percent of the company's shares, said in a letter to the board Tuesday that the expiration of Jeffries' term is an opportunity for the board to set a new direction for the company. Engaged Capital, a young activist investment firm led by former Relational Investors managing director Glenn Welling, said a sale of the company to a private equity buyer may represent the best option for shareholders. "However, as we have learned through discussions with industry insiders and private equity firms, Mr. Jeffries' presence represents a major stumbling block to a transaction," the activist investment firm said in the letter. Abercrombie's (ANF) shares, which have lost about 30 percent of their value this year, rose 6.4 percent to $36.20 by midday. Analysts have raised concerns about the company's ability to revitalize its merchandise, citing management's focus on cost-cutting, marketing and distribution instead of product and design. "A little fresh blood would definitely benefit the company," Morningstar (MORN) analyst Bridget Weishaar told Reuters. However, she said the board has been very supportive of Jeffries. "So, I'd be highly doubtful if this letter changes anything." Engaged Capital said there appeared to be no qualified successor within the company to replace 69-year-old Jeffries, who has been CEO for 16 years. His current contract includes a clause that he would receive over $100 million if the company changes control. Jeffries owned about 1.3 percent of Abercrombie's shares as of July 30. The company wasn't immediately available for comment. Engaged Capital said it owned about 400,000 shares of Abercrombie. The company has about 76.4 mil

Best Tech Companies To Buy Right Now: QuickLogic Corporation(QUIK)

QuickLogic Corporation, a fabless semiconductor company, develops and markets low power customizable semiconductor solutions for tablets, smartbooks, netbooks, cloudbooks, smartphones, datacards, and mobile enterprise products. Its solutions enable original equipment manufacturers and original design manufacturers to add new features, extend battery life, and enhance the visual experience of their handheld mobile devices. The company designs customer specific standard products, which are customer-specific solutions that include a combination of silicon solution platforms, Proven System Blocks (PSBs), customer-specific logic, software drivers, and firmware. It primarily offers two platform families, ArcticLink and PolarPro, which are standard silicon products. The company?s PSBs include Visual Enhancement Engine and Display Power Optimizer technologies; SDHD/eMMC Host Controllers; USB 2.0 On-The-Go with PHY; MDDI Client with PHY; high speed UARTs; pulse width modulators; S PI and I2C hosts, display-specific functions, such as RGB-split and frame recyclers; and Data Performance Manager for accelerated sideloading times. QuickLogic?s PSBs allows system designers to combine multiple discrete chips onto a single CSSP, simplifying design and board layout, lowering bill of materials cost, and accelerating time-to-market. The programmable fabric of the platforms is used for adding differentiated features, as well as provide flexibility to address hardware-based product requirements. The company markets its products through a direct sales force and has sales offices in the United States, the United Kingdom, China, Japan, and Taiwan; and has development offices in Canada and India. QuickLogic Corporation was founded in 1988 and is headquartered in Sunnyvale, California.

Advisors' Opinion:

• [By Paul McWilliams]

  QuickLogic (QUIK) has posted exceptional new product growth in 2013, and now claims Samsung as a direct customer.

  While I think the drivers that delivered the goods in 2013, will continue to work to QuickLogic's favor in 2014, the real kicker in this equation is, QuickLogic is the only company in the world that has developed a sensor hub that is low enough power to deliver the vast benefits we can realize from Always-on Context Aware sensor fusion.

Best Tech Companies To Buy Right Now: Phonetime Inc (PHD.TO)

Tellza Communications Inc., a telecommunications carrier, provides business to business services worldwide. The company offers international and domestic switched voice services to the telecommunication operators and voice service providers. It also provides long distance telecommunication services to telecommunications providers; outsourced telecommunications services at the carrier level; wholesale carrier services; retail voice services, which offer voice termination through TDM or IP interconnections; and domestic SIP termination services. The company�s customers and suppliers include fixed line operators, mobile operators, and retail and VoIP service providers. The company was formerly known as Phonetime Inc. and changed its name to Tellza Communications Inc. in October 2013. Tellza Communications Inc. was founded in 1994 and is based in Toronto, Canada.

Best Tech Companies To Buy Right Now: FAL Exploration Corp (MINA.PK)

FAL Exploration Corp., formerly Apps Genius Corp, incorporated on December 17, 2009, is engaged in the business plan to develop and operate a crowdfunding platform. On April 19, 2012, the Company acquired the domain name GetFunded.com in order to explore potential opportunities in crowdfunding.

The Company has two vertical websites which have been released and are operational. Crowdfunding describes the collective cooperation, attention, and trust by people who network and pool their resources, usually via the Internet, to support efforts initiated by other people or organizations.

Hot Medical Stocks For 2015

This weekend in Monaco the Only Watch 2013 charity auction event put over 30 watch lots on the block as bidders from all over the world fought for a slew of completely unique new watches. In support of the Duchenne Muscular Dystrophy medical charity, the Only Watch auction event occurs every two years and donates 100% of its proceeds to the charity. Now operated by well-known timepiece auctioneer Antiquorum, the Only Watch auction is a novel event because it not only asks brands to donate watches, but that they must offer completely novel ��iece unique��watches, or ones that are the very first piece in a limited edition.

An amazing press opportunity for the participating brands, Only Watch sees some of the world�� top watch makers present offer up extremely desirable pieces. For 2013 the far-and-away winner of the auction was famous Swiss watch brand Patek Philippe. The Only Watch 2013 auction event yielded a total of 5,066,000 Euros. An impressive figure, but it is important to note that 2,950,000 Euros of that (about 58%) amount is due to just one watch ��a Patek Philippe.

Hot Medical Stocks For 2015: Antares Pharma Inc (ATRS)

Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company�� subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.

In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol, for the treatment of overactive bladder. Antares also has a licensing agreement with Watson Watson Pharmaceuticals, Inc. (Watson) under which Watson will commercialize its topical oxybutynin gel 3% product in the United States and Canada. Its gel portfolio also includes Elestrin (estradiol gel) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies.

Pressure Assisted Injection Devices

The Company�� Pressure Assisted Injection Devices consists of three products: reusable needle-free injectors, disposable pressure assisted auto injectors and disposable pen injectors. Reusable needle-free injectors deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. The injector employs a disposable pl! astic needle-free syringe, which offers liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle.

Disposable pressure assisted auto injectors is a technology of controlled pressure delivery of drugs into the body utilizing a spring power source. The Vibex is designed to provide fast subcutaneous or intramuscular injections of up to 0.5ml with minimal discomfort and improved convenience in conjunction with the enhanced safety of a shielded needle. Disposable pen injectors are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The devices contain mechanisms that specify the dose to be delivered by defining the amount of movement by the stopper in the cartridge with each device actuation.

The Vision/Tjet has been sold for use in more than 30 countries to deliver either insulin or hGH. The product features a reusable, spring-based power source and disposable needle-free syringe, which acts as the pathway for the injectable drug through the skin and allows for viewing of the medication dose prior to injection. The product is also reusable, with each device designed to last for approximately 3,000 injections (or approximately two years) while the needle-free syringe, when used with insulin or hGH, is disposable after approximately one week when used by a single patient for injecting from multi-dose vials. The Vision/Tjet administers injectables by using a spring to push the active ingredient in solution or suspension through a micro-fine opening in the needle-free syringe. The opening is approximately half the diameter of a 30-gauge needle. The Vision/Tjet is primarily used in the United States, Europe, Asia and Japan.

Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies. Its Vibex disposable product combines a low-energy, spr! ing-based! power source with a hidden needle, which delivers up to 0.5ml of the needed drug solution subcutaneously or intramuscularly. Antares is also developing a Vibex MTX auto injector for delivery of methotrexate for treatment of rheumatoid arthritis. The Company�� multi use, disposable pen injector complements its portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi- dose cartridges. The disposable pen is in the stage of development where devices are being used in clinical evaluations.

Transdermal Products

The Company�� ATD system penetrates the skin to deliver a variety of treatments. The gels consist of a hydro-alcoholic base, including a combination of permeation enhancers. Products being developed/ commercialized include Anturol, Elestrin and Nestragel. Elestrin is a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Its other injectable drugs that are presently self-administered and may be suitable for injection with its systems include therapies for the prevention of blood clots and treatments for multiple sclerosis, migraine headaches, inflammatory diseases, impotence, infertility, acquired immune deficiency symdrome (AIDS) and hepatitis.

The Company competes with Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical, Vetter Pharma, Bioject Medical Technologies Inc., The Medical House PLC, Watson, Abbott, Eli Lilly, Auxillium, Inc., Endo Pharmaceuticals, Teva, Mylan, Roxane, Bedford Labs, APP Pharmaceuticals, Hospira, Pfizer, GSK/Astellas, Warner Chilcott and Allergan.

Advisors' Opinion:

• [By Luke Jacobi]

  Antares Pharma (NASDAQ: ATRS) added 6.65 percent to close at $4.33 following the announcement that an FDA decision is expected on its drug on October 14. Equities

• [By Keith Speights]

  Antares Pharma (NASDAQ: ATRS  ) announced its first-quarter results �Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company's results.

Hot Medical Stocks For 2015: Clovis Oncology Inc (CLVS)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.

CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Advisors' Opinion:

• [By Keith Speights]

  Give me a double
  The Motley Fool's David Williamson summed up the great week for Clovis Oncology (NASDAQ: CLVS  ) perfectly in his headline a few days ago: "1 Biotech + 2 Cancer Drugs = 100% Pop." While that 100% pop drifted down to 96% by the end of the week, Dave hit the nail on the head.

• [By John Udovich]

  Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:

  Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron�� where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs�Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech�IPO Setbacks. FierceBiotech has�summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia,�slashed its asking price on 6.9 million shares to $12 a share to raise $82 million�from a range of $16 to $19 a share while�Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer,�has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming�Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its�new, patient-friendly approach for delivering inhaled nitric oxide on the

10 Best Shipping Stocks To Invest In Right Now: Cerus Corporation(CERS)

Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company?s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. Cerus Corporation has collaboration agreements with Baxter International, Inc.; and BioOne Corporation, as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California.

Advisors' Opinion:

• [By Seth Jayson]

  Cerus (Nasdaq: CERS  ) is expected to report Q1 earnings on April 30. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cerus's revenues will expand 15.0% and EPS will remain in the red.

Hot Medical Stocks For 2015: Clovis Oncology Inc (CLVS.O)

Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.

CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine

CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hE NT1 levels.

CO-1686-an Oral EGFR Mutant-Select! i! ve Inhibitor

CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.

The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line t reatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.

CO-338-a PARP Inhibitor

CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the o ral formulation, to determine an appropriate dose and s! chedu! le! .

The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.

Hot Medical Stocks For 2015: Inergetics Inc (NRTI.PK)

Inergetics, Inc., formerly Millennium Biotechnologies Group, Inc., incorporated on November 9, 2000, is a holding company for its sole operating subsidiary, Millennium Biotechnologies, Inc. (Millennium). The Company through its subsidiary Millennium, engages in the research, development, and marketing of specialized nutritional supplements as an adjunct to medical treatments for select medical conditions, as well as for athletes seeking improved recovery and advanced performance. The Company markets products, which are targeted toward immuno-compromised individuals undergoing medical treatment for diseases, such as cancer, as well as wound healing and post-surgical healing and geriatric patients in long-term care facilities among other conditions. In January 2013, the Company acquired Bikini Ready and SlimTrim brands from Whole Products Group.

The Company�� product portfolio include, Resurgex Select, Ready-To Drink Resurgex Essential and Ready-To-Drink Re surgex Essential Plus. Resurgex Select is a whole foods-based, calorically dense, high-protein powdered nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex Essential and Resurgex Essential Plus represent Millennium�� Ready-to-Drink product line and are being sold into the Long-Term Care geriatric markets.

Resurgex Select

Resurgex Select is a whole foods-based nutritional product that is designed to be used throughout the course of cancer treatment (chemotherapy, radiation, etc.), as many times patients lose weight and cannot consume adequate nutrition. This product combines dietary fiber (3 g), low sugar (5 g), and high protein (15 g) with no added antioxidants to be a high-calorie (350 calorie) supplement. It is available in three flavors (Vanilla Bean, Chocolate Fudge, and Fruit Smoothie) and each can be mixed with water, milk, juices, or in soft cold foods, such as yogurt, apple sauce or p udding.

Surgex

Surgex (www.surge! xs! ports.com), is a nutritional support formula that aims to address the concerns of many elite athletes who suffer from symptoms, such as fatigue, lean muscle loss, lactic acid buildup, oxidative stress, and stressed immune systems. This formula is designed to improve recovery parameters in efforts to enhance the performance of professional and collegiate athletes.

Resurgex Essential

The Essential line is a ready-to-drink alternative to Ensure and Boost designed to be marketed into the long-term care channel. Resurgex Essential has 250 whole food calories containing no corn syrup or corn oil. The product also contains fruit and vegetable extracts, and FOS Fiber to provide calories and taste.

The Company competes with Nestle and Abbott Laboratories Inc.

Hot Medical Stocks For 2015: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors' Opinion:

• [By Sean Williams]

  Take lung cancer, for instance, which currently has 29 compounds approved by the FDA -- including Celgene's (NASDAQ: CELG  ) Abraxane, which was approved as a first-line treatment for non-small-cell lung cancer in October. Abraxane was able to boost the overall response rate by 8% relative to placebo and, along with a handful of other NSCLC treatments, will be tough to unseat even if reolysin works effectively in treating NSCLC.

• [By David Williamson]

  Bluebird doesn't have any products in late stage trials, but its three drug-development programs are extremely intriguing. Is the hype for its shares justified, or is this another sign of a biotech bubble? And would investors possibly be better served taking a look at Bluebird's partner Celgene (NASDAQ: CELG  ) ?

Hot Medical Stocks For 2015: Fuse Science Inc (DROP.PK)

Fuse Science, Inc. ( Fuse Science), incorporated on September 21, 1988, is a consumer products holding company. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can be consumed orally, applied topically or delivered otherwise sublingually or transdermally, thereby bypassing the gastrointestinal tract and entering the blood stream directly. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. In December 2012, the Company launched its initial DROP products, PowerFuse, an energy formulation in a concentrated drop and ElectroFuse, an electrolyte formula in a concentrated drop, online, with the expansion into targeted retail distribution channels.

The Compan y is developing formulations and devices, which are compatible with alternative delivery systems for energy, medicines, vitamins and minerals, among other bioactives. These alternative systems include, but are not limited to, sublingual, transdermal and buccal drug delivery methods. use Science has developed and continues to advance, in conjunction with its scientific team, sublingual and transdermal delivery systems for bioactives that can effectively encapsulate and charge varying molecules in order to produce product formulations which can be consumed orally, applied topically or otherwise delivered sublingually or transdermally, thereby bypassing the gastrointestinal tract and entering the blood stream directly. The delivery technology is consists of encapsulation vesicles and ion exchange permeation enhancers. This technology utilizes a gradient across the mucosa membrane to help deliver the bioactive more efficiently through the mucosa.

The Company

Hot Medical Stocks For 2015: AmbiCom Holdings Inc (ABHI)

AmbiCom Holdings, Inc. (AmbiCom Holdings), formerly Med Control, Inc., incorporated on July 1, 2008, through its subsidiaries, is engaged in design and development of wireless products focusing on the wireless medical industry. The Company was a development-stage company organized to sell a product called Med Time, an electronic and portable device aimed to control the doses and schedules of medications taken by elderly individuals. On January 15, 2010, the Company completed the acquisition of AmbiCom Acquisition Corp. (AmbiCom). AmbiCom is a holding company whose operating company, AmbiCom, Inc., is a designer and developer of wireless products focusing on the wireless medical industry. AmbiCom purchases standard wireless products and designs and develops features and packaging to customize these products to their target original equipment manufacturer (OEM) markets. AmbiCom�� wireless device solutions and applications include infusion pumps, heart monitoring machines, and glucose meters.

AmbiCom sells its products through multi-channel distribution and original equipment manufacturer (OEM) channels. The Company delivers its medical device modules to OEM companies, such as Cardinal Health/Carefusion, and Roche. It outsources production of its products to manufacturers in Asia. The Company derives revenue from sales of its wireless device products. These products consist of routers, compact flash adapters/modules, universal serial bus (USB) adapters/modules, mini peripheral component interconnect (PCI) modules, PCI Express mini modules and mobile wireless products. It provides optimized wireless products to the medical industry, which has concentrated on using wireless solutions as a way to reduce healthcare costs as a whole.

Hot Medical Stocks For 2015: Bio-Matrix Scientific Group Inc (BMSN)

Bio-Matrix Scientific Group, Inc., incorporated on October 6, 1998, is a development stage company. The Company, through its wholly-owned subsidiary Regen BioPharma ,Inc., is engaged in the development of regenerative medical applications which it focuses to license from other entities up to the point of completion of Phase I and or Phase II clinical trials after which it would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The Company has begun development of HemaXellerate, a cellular drug designed to heal damaged bone marrow. HemaXellerate I (TM) is a patient-specific composition of cells that have been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies.

Advisors' Opinion:

• [By Bryan Murphy]

  If you're a small cap enthusiast looking for some budding ideas, you may not need to look any further than China GengSheng Minerals, Inc. (NYSEMKT:CHGS), Bio Matrix Scientific Group Inc. (OTCMKTS:BMSN), and MER Telemanagement Solutions Ltd. (NASDAQ:MTSL). All three have either pushed themselves to the brink of a breakout, if they haven't started one already. Here's a closer technical look at MTSL, BMSN, and CHGS, and what it's going to take to get them going if they're not going already.

Hot Medical Stocks For 2015: Autoimmune Inc (AIMM.PK)

AutoImmune Inc., incorporated in September 1988, is a healthcare company. The Company�� products are based on the principles of mucosal tolerance. The Company�� product is sold by Colloral LLC, the Company�� joint venture with Deseret, under the brand name Colloral, The Collagen Solution and Vital 3, and by Futurebiotics LLC under the brand name Vital 3. The other products which are in the development stage include MBP8298 (dirucotide), Oral Copaxone and AI 401.

The Company completed ten human clinical trials involving over 1,900 patients to investigate the use of Colloral as a pharmaceutical for treating symptoms of rheumatoid arthritis. The Company holds a joint venture with Deseret by forming Colloral LLC to manufacture market and sell Colloral as a dietary supplement. Colloral LLC holds a distributing agreement with Futurebiotics LLC for Colloral. Futurebiotics LLC markets the product under the brand name Vital 3. Colloral LLC also markets the pro duct under the Vital 3 brand through The Shopping Channel of Canada via on air segments and their Website.

The Company�� other products in the development stage include MBP8298 (dirucotide) for multiple sclerosis, which is in Phase III trials for secondary progressive multiple sclerosis; Oral Copaxone is in the research stage for multiple sclerosis, and AI 401 is in Phase III trials for Type 1 diabetes. The development of MBP8298 (dirucotide) is conducted by BioMS Medical Corporation (BioMS). In August 2000, BioMS tested patients in a Phase II/III (MAESTRO-01) clinical trial of its MBP8298 treatment for secondary progressive multiple sclerosis. It was conducted at 47 sites across Canada and Europe. In November 2006, BioMS enrolled in a Phase II clinical trial (MINDSET-01) of MBP8298 for treatment of relapsing remitting multiple sclerosis. It enrolled 218 patients at 24 sites in six countries for a 15 month trial.

The Company collaborated with Eli Lilly, which supports clinical testing of orally administer! e! d autoimmune-mediated (Type 1) diabetes product, AI 401. Eli Lilly completed three different Phase II clinical trials to demonstrate human proof of principle for AI 401. The United States study was a one-year, double-blind, placebo-controlled trial with more than 200 patients, designed to measure immunological changes, preservation of pancreatic function and time to insulin dependence. Its second Phase II trial, involving approximately 150 patients, was conducted in France. The third trial was conducted in Italy with approximately 80 patients. In addition, Eli Lilly provided AI 401 for the Diabetes Prevention Trial (DPT-1) conducted by the National Institutes of Health (NIH). During the year ended December 31, 2008, the clinical trial of intranasal insulin to delay or prevent the clinical onset of Type I diabetes, called the Diabetes Prediction and Prevention Project was conducted in Finland. As of January 1, 2009, 115 had been enrolled in this trial.

3 Death-Defying Dividend Stocks to Buy Now

Popular Posts: 3 Dividend Stocks to Sell Before It's Too Late4 Monthly Dividend Stocks for a Steady Diet of IncomeNaked Puts: Make a Grand This Month With Options Recent Posts: 3 Death-Defying Dividend Stocks to Buy Now RICK Stock: Rick’s Cabaret Might Have Legs 3 Dividend Stocks to Sell Before It's Too Late View All Posts

There is a lot of anxiety in the fixed income markets, which is especially unsettling for folks living on fixed incomes. 

Source: Flickr

Bond yields — forever the backbone of the fixed income investor — have vanished. But the entire concept of retirement investing is built on having investments that are considered safe. Retirees aren't crazy about risk; they want to know their life savings are safe in investments designed to offer capital preservation while throwing off that regular monthly income. 

However, they've been forced to move further out on the risk curve in order to replace those bond yields. That means many are now buying dividend stocks.

Of course, there is a wide range of dividend stocks out there. But for retirees who want safety, the best investments are companies that are both powerhouses and that have a long history of paying dividends — death-defying dividend stocks, if you will. I'm particularly focused on dividend stocks that maintained their payments during the financial crisis.

Here are three of the best dividend stocks if you’re seeking safety.

Death-Defying Dividend Stocks: Coca-Cola (KO)

Dividend Yield: 2.92%

Coca-Cola Co. (KO) definitely checks all the boxes for our list of death-defying dividend stocks. When I first began investing in 1995, KO stock was my first purchase. I wanted safety, security and dividend payments for my first foray. And this stock has only improved since that day some 19 years ago.

Dividend stocks like Coca-Cola always ran the risk of resting on their laurels, but KO has done anything but that. In fact, it’s mind-blowing how many brands and beverages the company now owns. Management remains on the cutting edge too, as evidenced by its recently-announced 10% ownership stake in Green Mountain Coffee Roasters (GMCR).

Today, Coca-Cola stock pays a nearly 3% yield, and its dividend remained solidly in place during the financial crisis. In fact, KO has paid a dividend since 1920. For the cherry on top, its free cash flow runs between $7 billion and $8 billion dollars annually, so Coca-Cola can easily afford the $4.6 billion it pays out.

Death-Defying Dividend Stocks: Dupont (DD)

Dividend Yield: 2.82%

Dupont (DD), which by the way is short for E.I. du Pont de Nemours & Company, is also one of the most solid dividend stocks you will find. Sure, a chemical company isn't the sexiest play in the world, and it is amazing that all the chemophobia and negative publicity surrounding chemicals hasn't really affected its business.

But like KO, DD stock has remained on the forefront of changing times. Dupont is slowly transforming its straight-up chemical business into a more agricultural-driven entity.  The company’s agribusiness saw an 18% increase in sales in the most recent quarter, driven by its newest products: corn seed and insecticides.

That’s just one reason DD, with its 2.8% yield, is still one of the best dividend stocks. Plus, the payout has historically been about 50% of free cash flow.

Death-Defying Dividend Stocks: Genuine Parts Co. (GPC)

Dividend Yield: 2.53%

One of my favorite boring companies also makes our list of the best dividend stocks for retirees. Genuine Parts Co. (GPC) is a name you may not know … but you have probably heard of its 1,100 Napa Auto Part stores.

I love auto parts companies because there are zillions of cars on the road, all of which age, need maintenance and therefore need parts. There's an endless supply … kind of like coffee drinkers and smokers.

Plus, GPC has a lot to like that specific to the world of dividend stocks. Its payout is solid as a rock, yielding over 2.5%, and rarely does that amount exceed 50% of free cash flow.

As of this writing, Lawrence Meyers did not hold a position in any of the aforementioned securities. Alas, he sold his Coke stock in 1999.

5 Health Care Provider Stocks to Buy Now

Popular Posts: 4 Commercial Banking Stocks to Buy Now8 Pharmaceutical Stocks to Buy Now7 Biotechnology Stocks to Buy Now Recent Posts: 5 Best Sectors to Watch This Week 5 Health Care Provider Stocks to Buy Now 3 Grocery and Staples Retail Stocks to Buy Now View All Posts

The grades of five health care provider stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

UnitedHealth Group Incorporated () is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. UnitedHealth provides healthcare services, including health benefit plans and services to national employers, non-employer based insurance options and health and well-being services for individuals aged 50 and older. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, UNH also gets A’s. .

Cardinal Health, Inc. () earns an A this week, jumping up from last week’s grade of B. Cardinal Health provides products and services related to the safety and productivity of healthcare. .

This is a strong week for Laboratory Corporation of America Holdings (). The company’s rating climbs to A from the previous week’s B. Laboratory Corporation of America Holdings is a clinical laboratory company that offers clinical laboratory tests used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. .

HCA Holdings, Inc. () ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. HCA Holdings operates acute care hospitals, outpatient facilities, clinics and other patient care delivery settings. .

This week, The Providence Service Corporation () pushes up from a C to a B rating. The Providence Service provides and manages government sponsored social services and non-emergency transportation services. .

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.

McEvoy resigns at Woodbury

Advisor Group continues to see movement in the executive suite.

Pat McEvoy resigned last week as chief executive of Woodbury Financial Services Inc., Larry Mark, a spokesman for American International Group Inc., which owns Advisor Group, confirmed Monday. Mr. Mark did not comment on the reasons for the resignation.

Woodbury is one of four independent broker-dealers that make up Advisor Group, one of the largest networks of independent B-Ds in the industry with a total of 5,408 reps .

Erica McGinnis, CEO of Advisor Group, will temporarily replace Mr. McEvoy while the firm looks for a successor.

Mr. McEvoy’s resignation is the second significant change in the leadership of Advisor Group in the past four months. In September, long-time Advisor Group CEO Larry Roth stepped down to become CEO of Realty Capital Securities LLC, the broker-dealer and wholesaler for Nicholas Schorsch’s nontraded real estate investment trusts and other alternative investments.

In October, Advisor Group tapped Ms. McGinnis, its compliance chief, to replace Mr. Roth.

A year ago, AIG completed its purchase of Woodbury Financial from The Hartford Financial Services Group Inc.

“I would like to thank Pat for his contributions to Woodbury over the years, especially during the recently completed integration of the firm into the Advisor Group network,” Ms. McGinnis said in a statement. “I wish him the best in the next phase of his career.”

Stocks to Watch: Aramark, C.H. Robinson, Merck

Among the companies with shares expected to actively trade in Wednesday’s session are Aramark Holdings Corp.(ARMK), C.H. Robinson Worldwide Inc.(CHRW) and Merck(MRK) & Co.

Aramark said its fiscal first-quarter earnings rose 4.5% as the food-services company posted broad-based revenue growth in its first report as a public company. Results beat estimates, pushing shares up 6% to $26.50 premarket.

C.H. Robinson’s fourth-quarter profit fell 64% as the transportation and logistics company’s truckload net revenue margin fell amid higher costs per-mile. Results missed Wall Street’s expectations, sending shares down 8.1% to $53.88 premarket.

Merck said its fourth-quarter earnings fell 14% on weaker sales as the drugmaker also was hit by expenses related to its cost-cutting efforts. Results missed estimates, and the company’s sales outlook for the year was weak. Shares rose 1.6% to $54.36 premarket as the company also said it entered three separate collaboration agreements with other drugmakers to evaluate its investigational MK-3475 immunotherapy cancer treatment.

3M Co.(MMM) unveiled a new $12 billion share-buyback program, continuing the industrial-products maker’s practice of using cash flow to fund shareholder-friendly moves. Shares edged up 1.2% to $128.28 premarket.

Top 5 Low Price Companies To Watch In Right Now

Aflac Inc.'s(AFL) fourth-quarter earnings rose 16% but a weaker yen and dollar exchange rate continued to weigh on the company’s core operations in Japan. Shares edged down 2.4% to $60 premarket.

Genworth Financial Inc.'s(GNW) fourth-quarter profit rose 24% as the life and mortgage insurer cut expenses and reported higher net investment gains. The latest results topped expectations. Shares rosed 3.2% to $15 premarket.

Hain Celestial Group Inc.(HAIN) said its fiscal second-quarter earnings rose 30% on higher revenue, although its gross margin narrowed. But the top line missed analysts’ expectations, sending shares down 6.6% to $85.01 premarket.

IAC/InterActiveCorp(IACI). said its fourth-quarter earnings jumped 89% as the Internet firm managed to offset a decline in search and media revenue with cost cutting. Revenue missed estimates, sending shares down 5.6% to $65 in light premarket trading.

Myriad Genetics Inc.(MYGN) said it has agreed to acquire Crescendo Bioscience Inc. for $270 million in cash as the biopharmaceutical company looks to expand into the high-growth autoimmune market. Shares climbed 12% to $30.35 premarket.

Tableau Software Inc.(DATA) swung to a surprise fourth-quarter profit as the business software maker’s revenue surged again. The company’s adjusted earnings and revenue beat expectations, pushing shares up 12% to $88.70 premarket.

Usana Health Sciences Inc.'s(USNA) fourth-quarter profit increased 9.9% as the nutritional-products maker posted higher global sales, results that easily exceeded Wall Street’s expectations. Shares surged 15% to $67.35 premarket.

Xoom Corp.(XOOM) swung to a fourth-quarter profit as the international money-transfer provider reported a jump in revenue. But the company’s full-year earnings outlook fell short of Wall Street’s expectations. Shares dropped 13% to $24.46 premarket.

Charter Communications Mulls Sweeter Bid for Time Warner Cable: Reuters

Seeing how its initial bid of $132.50 per share ($37.3 billion) for Time Warner Cable Inc. (NYSE: TWC) produced an immediate rejection, cable operator Charter Communications Inc. (NASDAQ: CHTR) is reported to be considering sweetening its offer to somewhere in the low $140s.

According to an exclusive report from Reuters, people familiar with the matter say that Charter has been discussing a price of $142.50, likely as a result of conversations with existing Time Warner shareholders. Time Warner has said that it will not consider any offer at less than $160 a share, but some of the company’s large shareholders could do some arm-twisting to get the company to look at a lower bid.

The third player in this game is Comcast Corp. (NASDAQ: CMCSA), which is said to have agreed to purchase some of Time Warner’s assets from Charter if that company can make the acquisition. Comcast is interested in Time Warner’s cable operations in New York City and parts of New England.

Top 5 Cheap Companies To Invest In Right Now

As total cable subscriber numbers decline, size becomes a paramount concern among cable operators. Comcast and Time Warner are numbers one and two in subscriber numbers, and Time Warner has let it be known that it would prefer a combination with Comcast rather than a deal with Charter. Regulatory approval of such a deal would be more difficult, unless a third party — say, Charter — were involved and Time Warner’s assets could be split up before a deal is approved.

In general, a three-way deal among Charter, Time Warner and Comcast could have an easier path through the regulatory process. Provided that Charter can get its bid up to $142.50, or perhaps even $145 a share, there is not a lot of reason for Time Warner to continue resisting. Unless the idea of being bought out by a smaller rival offends some egos.

Shares of Time Warner traded up about 2.3% in Monday’s premarket, at $136.30 in a 52-week range of $84.57 to $139.85. Shares of Charter and Comcast were inactive Monday morning.

Seasonality

I hope everyone out there in Readerland had a fine Thanksgiving. I certainly did, visiting family in California. With a real highlight being a drive up Highway One. In my view truly the most beautiful drive in America.

And now on to the subject at hand. There is a great deal of seasonality in this business. Hugely busy in the new year as everyone begins afresh. Then earnings season, usually followed by summer doldrums. More earnings, sometimes with events around October. Then, when December comes there is very little to do. Every professional trader and trading house is just interested in getting their books in order. Locking in profits, taking what losses they need to getting their tax situation in order, etc. Almost no one is willing to take on new risk. Everyone waits for January when the guns are reloaded and the books are clear.

What that means for you is much the same. The market will be thin and illiquid until January. There is little reason to take on new risks or open new positions. As I said back in March, "when there is nothing to do, do nothing". The worst mistake you can make is to trade a thin market out of boredom or some theoretical need to trade.

What that means for me and this column is there will very likely not be a new column every day until January. I will post year end summary and review unless something happens in the market that truly needs comment.

This does not mean, however, that I am unavailable to my students, mentees, or even casual readers. I will happily answer any and all questions you may have. It may seem like heresy, but in the holiday month there is actually something more important than money or the market

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Top Safest Companies To Watch In Right Now

Posted-In: Markets

Originally posted here...

  Around the Web, We're Loving... Lightspeed Trading Presents: Thunder and Tubleweeds: Trading Techniques for the New Market Enviroment Pope Francis Rips 'Trickle-Down' Economics Come See How the Pro's Trade in this Exclusive Webinar Wynn, MGM, Other Casino Giants Vying For U.S. Turf What Should You Know About AMZN? Most Popular It's Official: Apple is in Positive Territory for the Year Earnings Expectations For The Week Of December 2 Report: Apple iPhone Shipments Up in 3Q 2013 Latest IBM Data Good For Apple, Bad for Social Media Slideshow: Apple Shunned Black Thursday, Microsoft Sells 1M Xboxes And More From The Last Week Of November Morning Market Losers Related Articles () Energy Fuels to List Common Stock on NYSE MKT Federal Reserve Board Approves Investors Bancorp Proposed Acquisition of Roma Financial Oil States Acquires Quality Connector Systems Market Wrap For December 2: Markets Sluggish on Cyber Monday Benzinga's M&A Chatter for Monday December 2, 2013 Ascena Retail Group Rises 5% After Q1 Earnings Beat View the discussion thread. Partner Network